Faruqi & Faruqi Investigating Significant Drops in Tvardi's Stock Value Following Clinical Trial Results
In a notable turn of events, Faruqi & Faruqi, LLP, a well-respected national securities law firm, has embarked on an investigation into Tvardi Therapeutics, Inc. This investigation comes in the wake of a dramatic downturn in Tvardi's stock price, which saw a staggering plunge of over 80% after the release of concerning preliminary data from a key clinical trial.
On October 13, 2025, the shares of Tvardi Therapeutics faced a significant drop following results from the Phase 2 REVERT clinical trial administering TTI-101, a treatment aimed at tackling idiopathic pulmonary fibrosis (IPF). The trial was primarily focused on assessing critical safety metrics and exploring changes in lung function, a key concern for patients battling this challenging condition. Unfortunately, the data disclosed indicated that the trial failed to meet its defined objectives.
The clinical trial's findings showed that the preliminary safety data and the exploratory efficacy results, particularly concerning changes in Forced Vital Capacity (FVC), did not support the efficacy of TTI-101. Investors had anticipated more favorable outcomes, but the revealed data pointed to a disparity in patient baseline characteristics across the treatment arms, raising questions about the trial's overall effectiveness. The lower percent predicted FVC in placebo-treated patients compared to those treated with TTI-101 underscores the gravity of the situation.
In light of these developments, James (Josh) Wilson, a partner at Faruqi & Faruqi, has reached out to affected investors to discuss their legal rights. Wilson emphasizes the importance of awareness among those who have suffered losses as a result of their investment in Tvardi. The firm, known for recovering hundreds of millions in investor losses since its inception in 1995, invites investors to directly contact them for assistance. They can do so by reaching Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
This investigation serves as a critical reminder of the inherent risks associated with investing in clinical trials and biotechnology firms, where outcomes can significantly impact stock value overnight. Investors are encouraged to duly consider their options and remain informed about their rights and potential claims involving stocks impacted by clinical trial results.
Faruqi & Faruqi, LLP enjoys a strong reputation in securities litigation, with offices spread across New York, Pennsylvania, California, and Georgia. Their commitment to protecting investors' interests has made them a trusted choice for those seeking recourse after such dramatic setbacks. If you are an investor seeking further information regarding this investigation or your options, visit Faruqi's website for more details.
Twitter, LinkedIn, and Facebook users can also follow updates regarding this situation and other relevant investor information.
As the situation evolves, affected stakeholders are urged to stay informed and consider the benefits of legal consultation. This is especially vital in the fast-paced world of pharmaceutical development, where unforeseen challenges can arise, impacting both health prospects and financial securities alike.
On October 13, 2025, the shares of Tvardi Therapeutics faced a significant drop following results from the Phase 2 REVERT clinical trial administering TTI-101, a treatment aimed at tackling idiopathic pulmonary fibrosis (IPF). The trial was primarily focused on assessing critical safety metrics and exploring changes in lung function, a key concern for patients battling this challenging condition. Unfortunately, the data disclosed indicated that the trial failed to meet its defined objectives.
The clinical trial's findings showed that the preliminary safety data and the exploratory efficacy results, particularly concerning changes in Forced Vital Capacity (FVC), did not support the efficacy of TTI-101. Investors had anticipated more favorable outcomes, but the revealed data pointed to a disparity in patient baseline characteristics across the treatment arms, raising questions about the trial's overall effectiveness. The lower percent predicted FVC in placebo-treated patients compared to those treated with TTI-101 underscores the gravity of the situation.
In light of these developments, James (Josh) Wilson, a partner at Faruqi & Faruqi, has reached out to affected investors to discuss their legal rights. Wilson emphasizes the importance of awareness among those who have suffered losses as a result of their investment in Tvardi. The firm, known for recovering hundreds of millions in investor losses since its inception in 1995, invites investors to directly contact them for assistance. They can do so by reaching Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
This investigation serves as a critical reminder of the inherent risks associated with investing in clinical trials and biotechnology firms, where outcomes can significantly impact stock value overnight. Investors are encouraged to duly consider their options and remain informed about their rights and potential claims involving stocks impacted by clinical trial results.
Faruqi & Faruqi, LLP enjoys a strong reputation in securities litigation, with offices spread across New York, Pennsylvania, California, and Georgia. Their commitment to protecting investors' interests has made them a trusted choice for those seeking recourse after such dramatic setbacks. If you are an investor seeking further information regarding this investigation or your options, visit Faruqi's website for more details.
Twitter, LinkedIn, and Facebook users can also follow updates regarding this situation and other relevant investor information.
As the situation evolves, affected stakeholders are urged to stay informed and consider the benefits of legal consultation. This is especially vital in the fast-paced world of pharmaceutical development, where unforeseen challenges can arise, impacting both health prospects and financial securities alike.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.